During the past decade, Hickman Cancer Center conducted 67 clinical trials. In the 10-year time frame, 67 clinical trials started and 147 clinical trials were completed, i.e. on average, 219.4% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 46 clinical trials were completed. i.e. 170.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hickman Cancer Center" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 84 trials, followed by "National Cancer Institute (NCI)" with 83 trials sponsored, "SWOG Cancer Research Network" with 33 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 18 trials sponsored and "Radiation Therapy Oncology Group" with 18 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hickman Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 173 trials as a collaborator, "NCIC Clinical Trials Group" with 17 trials as a collaborator, "NRG Oncology" with 16 trials as a collaborator, "Cancer and Leukemia Group B" with 15 trials as a collaborator and "SWOG Cancer Research Network" with 12 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "Hickman Cancer Center" are "Breast Cancer" (40 trials), "Lung Cancer" (18 trials), "Unspecified Adult Solid Tumor, Protocol Specific" (14 trials), "Lymphoma" (10 trials) and "Recurrent Breast Carcinoma" (10 trials). Many other conditions were trialed in "Hickman Cancer Center" in a lesser frequency.

Most popular intervention types in "Hickman Cancer Center" are "Drug" (217 trials), "Other" (130 trials), "Biological" (107 trials), "Procedure" (42 trials) and "Radiation" (35 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (56 trials), "Quality-of-Life Assessment" (38 trials), "placebo" (34 trials), "Bevacizumab" (18 trials) and "Paclitaxel" (18 trials). Other intervention names were less common.

The vast majority of trials in "Hickman Cancer Center" are 205 trials for "All" genders, 41 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are NaN active trials in "Hickman Cancer Center". undefined are not yet recruiting, 33 are recruiting, 67 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 135 completed trials in Hickman Cancer Center, 1 suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Hickman Cancer Center, 10 "Phase 1" clinical trials were conducted, 110 "Phase 2" clinical trials and 130 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".